
Keywords: Eliglustat; Cerdelga; Carcinogenicity; Glucosylceramide synthase inhibitor; Gaucher disease; Lysosomal storage disease; FDA CAC; Food & Drug Administration Executive Carcinogenicity Assessment Committee; GD1; type 1 Gaucher disease; GL-1; glucosylceramide